Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies.
- Author:
Min Jeong LEE
1
;
In Gyu HWANG
;
Joung Soon JANG
;
Jin Hwa CHOI
;
Byeong Bae PARK
;
Myung Hee CHANG
;
Seung Tae KIM
;
Se Hoon PARK
;
Myoung Hee KANG
;
Jung Hun KANG
Author Information
1. Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Korea.
- Publication Type:Original Article
- Keywords:
Stomach neoplasms;
Docetaxel;
Oxaliplatin;
Irinotecan
- MeSH:
Camptothecin;
Disease-Free Survival;
Humans;
Korea;
Multivariate Analysis;
Organoplatinum Compounds;
Retrospective Studies;
Stomach Neoplasms;
Taxoids
- From:Cancer Research and Treatment
2012;44(4):235-241
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Little is known about outcomes in the use of third-line chemotherapy in cases of advanced gastric cancer (AGC). The primary aim of this retrospective study was to evaluate outcomes of docetaxel-based chemotherapy in patients with AGC that progressed after both oxaliplatin-based and irinotecan-based regimens. MATERIALS AND METHODS: Eligible patients were those with AGC who had previous chemotherapy including fluoropyrimidine and oxaliplatin as well as fluoropyrimidine and irinotecan and who received subsequent docetaxel-based chemotherapy. Thirty-five patients were retrospectively recruited from 5 medical centers in Korea. Patients received either weekly or 3 weekly with docetaxel +/- cisplatin. RESULTS: Thirty-one out of 35 patients were evaluated for treatment response. A total of 94 cycles of chemotherapy (median, 2; range, 1 to 7) were administered. The overall response rate was 14.3%, and the disease control rate was 45.7%. The median progression-free survival (PFS) was 1.9 months (95% confidence interval [CI], 1.1 to 2.7 months). The median overall survival (OS) was 3.6 months (95% CI, 2.8 to 4.4 months). PFS and OS were significantly prolonged in patients of the Eastern Cooperative Oncology Group, with performance status of 0 or 1 in multivariate analysis (PFS: hazard ratio[HR], 0.411; 95% CI, 0.195 to 0.868; p=0.020 and OS: HR, 0.390; 95% CI, 0.184 to 0.826; p=0.014, respectively). Four of the 35 patients enrolled in the study died due to infection associated with neutropenia. CONCLUSION: Our findings suggest that salvage docetaxel-based chemotherapy is a feasible treatment option for AGC patients with good performance status (PS), whereas chemotherapy for patients with poor PS (PS< or =2) should be undertaken with caution for those who previously failed oxaliplatin- and irinotecan-based regimens.
